

U.S. Induced Pluripotent Stem Cells (iPSCs) Market - Industry Trends and Forecast to 2031

Market Report | 2023-12-01 | 100 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

The U.S. induced pluripotent stem cells (iPSCs) market is expected to reach USD 488.42 million by 2031 from USD 218.87 million in 2023, growing at a CAGR of 10.7% in the forecast period of 2024 to 2031.

Market Segmentation

U.S. Induced Pluripotent Stem Cells (iPSCs) Market, By Model Type (ECM-Patterned PAA/ PDMS Substrates, Microgroove PDMS Substrates, Strained Membranes, 3D Scaffolds, Free-Floating Hydrogel Constructs, and EHTS), Material (Natural Hydrogel Based Cardiac Models and Synthetic Fibrous Cardiac Models), Cell Source (Skin Cells and Blood Cells), Dimensional Type (2D and 3D), Application (Production of New Cardiac Tissue To Replace Tissue Destroyed By Infraction Or Other Diseases, Heart Failure, Ischemic Heart Disease, Arrhythmia, Cardiomyopathies, Valvular Heart Disease, Heart Disease Screening, and Others), End Use (Pharmaceutical & Biotechnology Companies, Academic and Government Research Institutes, Contract Development & Manufacturing Organizations, and Others), Distribution Channel (Direct Tender and Retail Sales) Country (U.S.) - Industry Trends and Forecast to 2031

Overview of U.S. Induced Pluripotent Stem Cells (iPSCs) Market Dynamics

Driver

- Technological advancement in regenerative medicine

Restraint

- Safety concerns and technical difficulties

Opportunity

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Increasing interest in personalized medicine

Market Players

Some of the major market players operating in the U.S. induced pluripotent stem cells (iPSCs) market are:

- Corning Incorporated
- Lonza
- MIMETAS
- CN Bio Innovations Ltd
- 3D BIOTEK LLC
- AXOL
- REPROCELL Inc.

Table of Contents:

TABLE OF CONTENTS

1	INTRODUCTION	11
1.1	OBJECTIVES OF THE STUDY	11
1.2	MARKET DEFINITION	11
1.3	OVERVIEW OF U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET	11
1.4	CURRENCY AND PRICING	12
1.5	LIMITATIONS	12
1.6	MARKETS COVERED	13
2	MARKET SEGMENTATION	15
2.1	MARKETS COVERED	15
2.2	YEARS CONSIDERED FOR THE STUDY	16
2.3	DBMR TRIPOD DATA VALIDATION MODEL	17
2.4	PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	20
2.5	DBMR MARKET POSITION GRID	21
2.6	MULTIVARIATE MODELLING	22
2.7	TYPE LIFELINE CURVE	23
2.8	MARKET END USER COVERAGE GRID	24
2.9	SECONDARY SOURCES	25
2.10	ASSUMPTIONS	25
3	EXECUTIVE SUMMARY	26
4	PREMIUM INSIGHTS	29
4.1	PESTEL ANALYSIS	30
4.2	PORTER'S FIVE FORCES	31
5	MARKET OVERVIEW	32
5.1	DRIVERS	34
5.1.1	TECHNOLOGICAL ADVANCEMENT IN REGENERATIVE MEDICINE	34
5.1.2	EXPANDING APPLICATIONS IN DRUGS DISCOVERY	34
5.2	RESTRAINTS	35
5.2.1	SAFETY CONCERNS AND TECHNICAL DIFFICULTIES	35
5.2.2	COMPETITION AND INTELLECTUAL PROPERTY ISSUES	36
5.3	OPPORTUNITIES	36

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.3.1 INCREASING INTEREST OF PERSONALIZED MEDICINE	36
5.3.2 INCREASING ADOPTION OF STEM CELL THERAPY	37
5.4 CHALLENGE	38
5.4.1 HIGH COST ASSOCIATED WITH STEM CELL THERAPIES	38
?	
6 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY MODEL TYPE	39
6.1 OVERVIEW	40
6.2 ECM PATTERNED PAA/PDMS SUBSTRATES	43
6.3 MICROGROOVE PDMS SUBSTRATES	43
6.4 STRAINED MEMBRANES	43
6.5 3D SACFFOLDS	43
6.6 FREE-FLOATING HYDROGEL CONSTRUCTS	43
6.7 EHTS	43
7 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY MATERIAL	44
7.1 OVERVIEW	45
7.2 NATURAL HYDROGEL- BASED CARDIAC MODELS	48
7.3 SYNTHETICS FIBROUS CARDIAC MODELS	48
7.3.1 POLYGLYCOLIC ACID (PGA)	48
7.3.2 POLY E-CAPROLACTONE (PCL)	48
7.3.3 POLYURETHANE	48
7.3.4 POLYLACTIC ACID (PLA)	49
7.3.5 OTHERS	49
8 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE	50
8.1 OVERVIEW	51
8.2 SKIN CELLS	54
8.2.1 FIBROBLAST	54
8.2.2 KERATINOCYTES	54
8.2.3 MELANOCYTES	54
8.2.4 NEURAL STEM CELLS	54
8.2.5 ADIPOSE DERIVE STEM CELLS	54
8.2.6 OTHERS	55
8.3 BLOOD CELLS	55
8.3.1 PERIPHERAL BLOOD MONOCLEAR CELLS	55
8.3.2 CORD BLOOD ENDOTHELIAL CELLS	55
8.3.3 CORD BLOOD STEM CELLS	55
8.3.4 OTHERS	55
9 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DIMENSIONAL TYPE	56
9.1 OVERVIEW	57
9.2 3D	60
9.3 SKIN CELLS	60
9.3.1 FIBROBLAST	60
9.3.2 KERATINOCYTES	61
9.3.3 MELANOCYTES	61
9.3.4 NEURAL STEM CELLS	61
9.3.5 ADIPOSE DERIVE STEM CELLS	61
9.3.6 OTHERS	61
9.4 BLOOD CELLS	61

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.4.1 PERIPHERAL BLOOD MONOCLEAR CELLS	62
9.4.2 CORD BLOOD ENDOTHELIAL CELLS	62
9.4.3 CORD BLOOD STEM CELLS	62
9.4.4 OTHERS	62
9.5 2D	62
9.5.1 SKIN CELLS	62
9.5.1.1 FIBROBLAST	63
9.5.1.2 KERATINOCYTES	63
9.5.1.3 MELANOCYTES	63
9.5.1.4 NEURAL STEM CELLS	63
9.5.1.5 ADIPOSE DERIVE STEM CELLS	63
9.5.1.6 OTHERS	63
9.5.2 BLOOD CELLS	64
9.5.2.1 PERIPHERAL BLOOD MONOCLEAR CELLS	64
9.5.2.2 CORD BLOOD ENDOTHELIAL CELLS	64
9.5.2.3 CORD BLOOD STEM CELLS	64
9.5.2.4 OTHERS	64
10 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION	65
10.1 OVERVIEW	66
10.2 PRODUCTION OF NEW CARDIAC TISSUE TO REPLACE TISSUES DESTROYED BY INFRACTION OR OTHER DISEASES	70
10.3 HEART FAILURE	70
10.4 ISCHEMIC HEART DISEASE	70
10.5 ARRYTHMIA	70
10.6 CARDIOMYOPATHIES	70
10.7 VALVULAR HEART DISEASE	70
10.8 HEART DISEASE SCREENING	70
10.9 OTHERS	70
11 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USE	71
11.1 OVERVIEW	72
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	75
11.3 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES	75
11.4 CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS	75
11.5 OTHERS	75
12 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL	76
12.1 OVERVIEW	77
12.2 DIRECT TENDER	80
12.3 RETAIL SALES	80
13 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY LANDSCAPE	81
13.1 COMPANY SHARE ANALYSIS: U.S.	81
14 SWOT ANALYSIS	82
15 COMPANY PROFILE	83
15.1 CORNING INCRPORATED	83
15.1.1 COMPANY SNAPSHOT	83
15.1.2 REVENUE ANALYSIS	83
15.1.3 PRODUCT PORTFOLIO	84
15.1.4 RECENT DEVELOPMENT	85
15.2 LONZA	86

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.2.1 COMPANY SNAPSHOT 86
- 15.2.2 REVENUE ANALYSIS 86
- 15.2.3 PRODUCT PORTFOLIO 87
- 15.2.4 RECENT DEVELOPMENT 88
- 15.3 MIMETAS 89
 - 15.3.1 COMPANY SNAPSHOT 89
 - 15.3.2 PRODUCT PORTFOLIO 89
 - 15.3.3 RECENT DEVELOPMENT 89
- 15.4 REPROCELL INC. 90
 - 15.4.1 COMPANY SNAPSHOT 90
 - 15.4.2 PRODUCT PORTFOLIO 90
 - 15.4.3 RECENT DEVELOPMENT 91
- 15.5 CN BIO INNOVATIONS 92
 - 15.5.1 COMPANY SNAPSHOT 92
 - 15.5.2 PRODUCT PORTFOLIO 92
 - 15.5.3 RECENT DEVELOPMENT 93
- 15.6 AXOL BIOSCIENCE LTD. 94
 - 15.6.1 COMPANY SNAPSHOT 94
 - 15.6.2 PRODUCT PORTFOLIO 94
 - 15.6.3 RECENT DEVELOPMENT 94
- 15.7 3D BIOTEK LLC. 95
 - 15.7.1 COMPANY SNAPSHOT 95
 - 15.7.2 PRODUCT PORTFOLIO 95
 - 15.7.3 RECENT DEVELOPMENT 96
- 16 QUESTIONNAIRE 97
- 17 RELATED REPORTS 100

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

U.S. Induced Pluripotent Stem Cells (iPSCs) Market - Industry Trends and Forecast to 2031

Market Report | 2023-12-01 | 100 pages | Data Bridge Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com